foxo4-dri senolytic 2024 animal model Frontiers FOXO4-DRI 10mg vial - Description
FOXO4 DRI 10mg vial Description RCpeptides Targeting Cellular Senescence in Aging and Age Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice PMC Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine PDF) Senolytic Peptide FOXO4 DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes PDF) The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI
Pay in 4 interest-free payments of $6.80 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10





